Özeş A R, Miller D F, Özeş O N, Fang F, Liu Y, Matei D, Huang T, Nephew K P
Molecular and Cellular Biochemistry Department, Indiana University, Bloomington, IN, USA.
Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, USA.
Oncogene. 2016 Oct 13;35(41):5350-5361. doi: 10.1038/onc.2016.75. Epub 2016 Apr 4.
The transcription factor nuclear factor kappa B (NF-κB) and the long non-coding RNA (lncRNA) HOTAIR (HOX transcript antisense RNA) have diverse functional roles in cancer. In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors. To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment. We demonstrate that ectopic expression of HOTAIR induces NF-κB activation during DDR and interleukin-6 and interleukin-6 expression, both key NF-κB target genes. We show that HOTAIR regulates activation of NF-κB by decreasing Iκ-Bα (NF-κB inhibitor) and establish that by inducing prolonged NF-κB activation and expression of NF-κB target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity. Our findings suggest that an NF-κB-HOTAIR axis drives a positive-feedback loop cascade during DDR and contributes to cellular senescence and chemotherapy resistance in ovarian and other cancers.
转录因子核因子κB(NF-κB)和长链非编码RNA(lncRNA)HOTAIR(HOX转录反义RNA)在癌症中具有多种功能作用。在本研究中,我们发现HOTAIR的上调诱导卵巢癌产生铂耐药性,并且在复发性铂耐药性卵巢肿瘤中观察到HOTAIR水平高于原发性卵巢肿瘤。为了研究HOTAIR在铂诱导的DNA损伤过程中的作用,我们监测了双链断裂情况,并发现HOTAIR的表达导致铂处理后DNA损伤反应(DDR)的持续激活。我们证明,HOTAIR的异位表达在DDR过程中诱导NF-κB激活以及关键的NF-κB靶基因白细胞介素-6和白细胞介素-6的表达。我们表明,HOTAIR通过降低Iκ-Bα(NF-κB抑制剂)来调节NF-κB的激活,并证实通过在DNA损伤期间诱导NF-κB的长期激活和NF-κB靶基因的表达,HOTAIR在细胞衰老和铂敏感性中起关键作用。我们的研究结果表明,NF-κB-HOTAIR轴在DDR过程中驱动正反馈环级联反应,并导致卵巢癌和其他癌症中的细胞衰老和化疗耐药性。
Front Immunol. 2021
Eur Rev Med Pharmacol Sci. 2019-11
Cancer Chemother Pharmacol. 2020-8
Exp Mol Med. 2025-8-14
Naunyn Schmiedebergs Arch Pharmacol. 2025-1-14
Cancer Cell Int. 2024-12-19
Med Oncol. 2024-12-13
Curr Protoc Hum Genet. 2015-1-20
Cancer Res. 2014-7-17